Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Lab has informed that the Board of Directors approved the Audited Standalone and Consolidated Financial Results of the Company for the Year ended March 31, 2024 and Limited Reviewed Financial Results of the Company for the Quarter ended March 31, 2024 at their meeting held on April 25, 2024, which are enclosed along with the Audit Reports (including Limited Review Reports) issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company. The financial results are also available on the website of the Company at www.lauruslabs.com and also on the websites of BSE and National Stock Exchange of India: www.bseindia.com and www.nseinda.com respectively. The Board Meeting commenced at 02.00 pm and concluded at 02.45 pm.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: